The US Patent and Trademark Office (USPTO) has granted a patent for Axcella Therapeutics’ long Covid treatment candidate AXA1125.
AXA1125 is a novel composition of endogenous metabolic modulators (EMMs) designed to simultaneously support metabolic, inflammatory and fibrotic pathways associated with fatigue.
In April, The Lancet published the results of Axcella’s Phase IIa trial, which showed that there were significant improvements in fatigue-based symptoms among patients living with long Covid following a four-week treatment period with AXA1125.
“In addition to further strengthening Axcella’s global intellectual property position regarding its proprietary composition of amino acids in AXA1125, today’s patent issuance further validates AXA1125’s formulation and its tie to treating PASC or long Covid, explicitly symptoms of fatigue,” said Bill Hinshaw, President and Chief Executive Officer of Axcella.
“We are pleased to have this additional designation as we pursue options to bring our investigational product forward for the benefit of the millions of people who continue to suffer from long Covid fatigue. The understanding of the disease continues to advance and show the importance of mitochondrial function and how a mitochondrial activator like AXA1125 has the potential to impact the issues these patients face.”
EMMs are a broad family of molecules, including amino acids, which fundamentally impact and regulate human metabolism.
Edited by Diana Spencer, Senior Digital Content Editor, Drug Discovery World
